These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 1301587

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands.
    van der Meijden PM, Debruyne FM, Steerenberg PA, de Jong WH, Doesburg W.
    Prog Clin Biol Res; 1989; 310():285-98. PubMed ID: 2505272
    [No Abstract] [Full Text] [Related]

  • 4. BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group.
    Debruyne FM, van der Meijden AP, Franssen MP.
    Prog Clin Biol Res; 1989; 303():435-46. PubMed ID: 2506556
    [No Abstract] [Full Text] [Related]

  • 5. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
    Debruyne FM, van der Meijden AP, Schreinemachers LM, Geboers AD, Franssen MP, van Leeuwen MJ, Steerenberg PA, de Jong WH, Ruitenberg EJ.
    Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662
    [No Abstract] [Full Text] [Related]

  • 6. BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of randomized prospective trial.
    DeBruyne FM, van der Meijden AP, Geboers AD, Franssen MP, van Leeuwen MJ, Steerenberg PA, de Jong WH, Ruitenberg JJ.
    Urology; 1988 Mar; 31(3 Suppl):20-5. PubMed ID: 3279698
    [Abstract] [Full Text] [Related]

  • 7. Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group.
    Rintala E, Jauhiainen K, Alfthan O.
    Prog Clin Biol Res; 1989 Mar; 310():271-4. PubMed ID: 2505270
    [No Abstract] [Full Text] [Related]

  • 8. Evaluation of clinical data in bladder cancer immunotherapy with Connaught BCG (ImmuCyst).
    Barreto L, Csizer Z, Sparkes JD.
    Dev Biol Stand; 1992 Mar; 77():229-31. PubMed ID: 1426667
    [Abstract] [Full Text] [Related]

  • 9. [Intravesical instillation in the treatment of superficial tumors of the bladder].
    Chopin DK.
    Prog Urol; 1998 Apr; 8(2):268-73. PubMed ID: 9615941
    [Abstract] [Full Text] [Related]

  • 10. [A prospective and randomized study of the complete response, index of recurrences and progression in superficial bladder carcinoma treated with mitomycin C alone versus mitomycin C and BCG alternatively].
    Gelabert-Mas A, Arango Toro O, Bielsa Gali O, Lladó Carbonell C.
    Arch Esp Urol; 1993 Jun; 46(5):379-82. PubMed ID: 8342972
    [Abstract] [Full Text] [Related]

  • 11. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897).
    Van der Meijden AP, Hall RR, Macaluso MP, Pawinsky A, Sylvester R, Van Glabbeke M.
    Eur Urol; 1996 Jun; 29(2):199-203. PubMed ID: 8647147
    [Abstract] [Full Text] [Related]

  • 12. Adriamycin versus BCG in superficial bladder cancer: a Southwest Oncology Group Study.
    Lamm DL, Crissmann J, Blumenstein B, Crawford ED, Montie J, Scardino P, Grossman HB, Stanisic T, Smith J, Sullivan J.
    Prog Clin Biol Res; 1989 Jun; 310():263-70. PubMed ID: 2672016
    [No Abstract] [Full Text] [Related]

  • 13. BCG versus thiotepa in non-CIS, stage Ta, T1 bladder cancer: rationale and design of ECOG trial.
    Fisher HA.
    Prog Clin Biol Res; 1989 Jun; 310():275-83. PubMed ID: 2505271
    [No Abstract] [Full Text] [Related]

  • 14. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H.
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [Abstract] [Full Text] [Related]

  • 15. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON, Shapiro A, Pode D, Sidi A, Nativ O, Leib Z, Witjes JA, van der Heijden AG, Naspro R, Colombo R.
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [Abstract] [Full Text] [Related]

  • 16. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.
    Martinez-Pineiro JA, Jimenez León J, Martinez-Pineiro L, Fiter L, Mosteiro JA, Navarro J, García Matres MJ, Cárcamo P.
    Prog Clin Biol Res; 1989 Mar; 310():237-52. PubMed ID: 2505269
    [Abstract] [Full Text] [Related]

  • 17. The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ.
    Brosman S.
    Prog Clin Biol Res; 1989 Mar; 310():193-205. PubMed ID: 2771993
    [No Abstract] [Full Text] [Related]

  • 18. A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group.
    Witjes JA, vd Meijden AP, Witjes WP, Doesburg W, Schaafsma HE, Debruyne FM.
    Eur J Cancer; 1993 Mar; 29A(12):1672-6. PubMed ID: 8398292
    [Abstract] [Full Text] [Related]

  • 19. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
    Järvinen R, Kaasinen E, Sankila A, Rintala E, FinnBladder Group.
    Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
    [Abstract] [Full Text] [Related]

  • 20. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer.
    Witjes JA, Caris CT, Mungan NA, Debruyne FM, Witjes WP.
    J Urol; 1998 Nov; 160(5):1668-71; discussion 1671-2. PubMed ID: 9783928
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.